What amount sold does KALM Therapeutics, Inc. report in Form D filings?

The latest linked filings report $590K sold across 1 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was KALM Therapeutics, Inc.'s most recent SEC filing?

KALM Therapeutics, Inc.'s most recent Form D filing was on 2024-08-09.

How many investors does KALM Therapeutics, Inc. have?

The most recent Form D filing lists 14 investor(s).

What type of securities does KALM Therapeutics, Inc. offer?

KALM Therapeutics, Inc.'s SEC Form D filings indicate equity offerings.

KALM Therapeutics, Inc.

CIK: 0002032945·Biotechnology·HUNTSVILLE, AL·Corporation·Founded 2024

Reported Sold

$590,380

Total Filings

Identified Offerings

Last Filed

Aug 9, 2024

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Aug 9, 2024Form D — New notice

Reported sold: $590,380 · Target: $590,380

Rule 506(b)·14 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

Latest reported sold across 1 identified offering

$590,380

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Chris Seibert

Related Person

Appears on 1 filing

Anuj Singhal

Related Person

Appears on 1 filing

Filing History

Date	Type	Offering target	Reported sold	Investors
Aug 9, 2024	New	$590,380	$590,380	14

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Khaya Biosciences, Inc.

Biotechnology

Offering target: $850,000

Filed Aug 13, 2026